Free Delivery Over $100
|
|
|||
|
||||
OverviewAdvances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. Full Product DetailsAuthor: Paul Fisher , Kenneth D. Tew (Professor and Chairman, Department of Cell and Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Volume: 113 Weight: 0.690kg ISBN: 9780123942807ISBN 10: 0123942802 Pages: 304 Publication Date: 10 May 2012 Audience: Professional and scholarly , Professional and scholarly , Professional & Vocational , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of ContentsThe AID dilemma: infection, or cancer? The microRNA regulatory network in normal- and HTLV-1-transformed T cells The multifaceted oncoprotein Tax: Sub-cellular localization, post-translational modifications and NF-?B activation Lynch or not Lynch? Is that always a question? Activation induced deaminase in antibody diversification and chromosome translocation Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed Molecular Logic Underlying Chromosomal Translocations, Random or non-Random?ReviewsPraise for the Serial: This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences. -- American Scientist Excellent, highly informative, in-depth reviews...expertly written, up-to-date, and well-referenced. -- Journal of Medicinal Chemistry This is a series that has a long tradition of excellence in the field of cancer biology. -- Doody's Publishing Reviews Author InformationProfessor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USAThe Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation. Tab Content 6Author Website:Countries AvailableAll regions |
||||
